Esperion Therapeutics Stock Technical Analysis
| ESPR Stock | USD 2.62 0.07 2.75% |
As of the 24th of March, Esperion Therapeutics registers 2.62 per share in market pricing. Volatility and momentum metrics display Variance of 18.78, standard deviation of 4.33, and Mean Deviation of 3.32. Quantitative signals are calculated from volatility clustering and momentum shifts. Relative strength metrics are assessed within peer group data.
Esperion Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Esperion, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to EsperionEsperion | Build portfolio with Esperion Stock |
Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 6.99 | Buy | 7 | Odds |
Current and historical analyst recommendations for Esperion Therapeutics are summarized from research sources. The view also includes average analyst consensus. Professional analyst coverage of Esperion Therapeutics provides individual investors with access to institutional-quality research. The spread between the highest and lowest Esperion price targets reflects the degree of analytical disagreement.
Earnings Share -0.11 | Revenue Per Share | Quarterly Revenue Growth 1.437 | Return On Assets | Return On Equity |
The market value of Esperion Therapeutics is measured differently than book value, which reflects Esperion accounting equity. Esperion Therapeutics' market capitalization is 654.87 M. At P/B 98.42, Esperion Therapeutics trades at a significant premium to book value. Enterprise value stands at 739.25 M. Intrinsic value reflects what Esperion Therapeutics' fundamentals imply about worth, which may differ from both price and book figure.
Distinguishing between Esperion Therapeutics' value and market price helps frame analytical expectations. This information is provided for contextual purposes.
What if' Analysis
Historical what-if analysis for Esperion Therapeutics is useful because it converts abstract timing questions into a structured review of past performance under changing entry and holding periods. The real value is perspective: it shows whether the thesis would have remained investable across different historical windows or depended too heavily on one favorable stretch.
| 12/24/2025 |
| 03/24/2026 |
Starting with 0.00 in Esperion Therapeutics on December 24, 2025 and exiting today would produce 0.00 in net return. This reflects a 0.0% net return in Esperion Therapeutics in total across 90 days. All data reflects available market observations. Esperion Therapeutics competes with or is related to SNDL, SIGA Technologies, Aquestive Therapeutics, Emergent Biosolutions, Corvus Pharmaceuticals, Olema Pharmaceuticals, and Orthofix Medical. Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patien... More
Upside and Downside Indicators for Esperion Therapeutics Summary
Upside and downside measures for Esperion Therapeutics frame directional pressure and range behavior. The indicators are presented as neutral context for price dynamics.
| Information Ratio | -0.09 | |||
| Maximum Drawdown | 22.95 | |||
| Value At Risk | -7.38 | |||
| Potential Upside | 6.38 |
Volatility and Risk Indicators for Esperion Therapeutics Signals
For Esperion Therapeutics, these risk indicators capture historical volatility and return dispersion patterns. Figures are sourced from market data feeds and exchange records.| Risk Adjusted Performance | -0.07 | |||
| Jensen Alpha | -0.25 | |||
| Total Risk Alpha | -0.08 | |||
| Treynor Ratio | -0.15 |
Experienced investors tracking Esperion Therapeutics' watch for mean reversion setups where price has deviated from its long-run average. Sentiment extremes, news events, or liquidity shocks are common catalysts for these temporary dislocations in Esperion Therapeutics.
Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.07 | |||
| Market Risk Adjusted Performance | -0.14 | |||
| Mean Deviation | 3.32 | |||
| Coefficient Of Variation | -1,002 | |||
| Standard Deviation | 4.33 | |||
| Variance | 18.78 | |||
| Information Ratio | -0.09 | |||
| Jensen Alpha | -0.25 | |||
| Total Risk Alpha | -0.08 | |||
| Treynor Ratio | -0.15 | |||
| Maximum Drawdown | 22.95 | |||
| Value At Risk | -7.38 | |||
| Potential Upside | 6.38 | |||
| Skewness | 0.0346 | |||
| Kurtosis | 0.8525 |
Esperion Therapeutics Backtested Returns
Esperion Therapeutics reflects an unstable price behavior across the analytical window. It has a Sharpe Ratio of -0.13, evidencing negative risk-calibrated returns. We identified twenty-four technical indicators influencing the company's volatility profile. Please analyze metrics such as Variance of 18.78, standard deviation of 4.33, and mean deviation of 3.32 to evaluate coherence across risk measures. The company has a Market Sensitivity (Beta) of 2.87, which means elevated sensitivity to broad market movements. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Esperion Therapeutics will likely underperform. At this point, Esperion Therapeutics has a negative expected return of -0.58%.
Auto-correlation | 0.54 |
Modest predictability
The autocorrelation profile for Esperion Therapeutics registers modest predictability between the two measured intervals. When lagged price patterns show consistency, they can serve as a partial input for modeling Esperion Therapeutics's near-term price behavior. A serial correlation of 0.54 indicates that about 54.0% of current Esperion Therapeutics price fluctuations can be explained by its historical price movements.
| Correlation Coefficient | 0.54 | |
| Spearman Rank Test | 0.52 | |
| Residual Average | 0.0 | |
| Price Variance | 0.15 |
The model reviews Esperion Therapeutics using price movement and volume trends. The dataset includes signals based on trend and relative strength.
Technical Analysis
This analysis covers thirty-seven data points across the selected time horizon. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Esperion Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Technical Analysis Methodology & Indicators
Technical analysis of Esperion Therapeutics evaluates price structure, momentum, and volatility clustering. Reduced trading volume may increase short-term pricing variability. Esperion Therapeutics has a market cap of 654.87 M, ROE of -2.61%.
Reported values for Esperion Therapeutics are derived from periodic company reporting and market reference feeds and then standardized for analysis. Where analyst coverage exists, consensus estimates are factored in. Refresh timing depends on source availability.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardEsperion Therapeutics Technical Indicators
A technical review of Esperion Therapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. A disciplined technical workflow separates stronger setups from noisier price action.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.07 | |||
| Market Risk Adjusted Performance | -0.14 | |||
| Mean Deviation | 3.32 | |||
| Coefficient Of Variation | -1,002 | |||
| Standard Deviation | 4.33 | |||
| Variance | 18.78 | |||
| Information Ratio | -0.09 | |||
| Jensen Alpha | -0.25 | |||
| Total Risk Alpha | -0.08 | |||
| Treynor Ratio | -0.15 | |||
| Maximum Drawdown | 22.95 | |||
| Value At Risk | -7.38 | |||
| Potential Upside | 6.38 | |||
| Skewness | 0.0346 | |||
| Kurtosis | 0.8525 |
March 24, 2026 Daily Trend Indicators
A technical review of Esperion Therapeutics can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. A disciplined technical workflow separates stronger setups from noisier price action.
| Accumulation Distribution | 0.03 | ||
| Daily Balance Of Power | 1.00 | ||
| Rate Of Daily Change | 1.03 | ||
| Day Median Price | 2.59 | ||
| Day Typical Price | 2.60 | ||
| Price Action Indicator | 0.07 | ||
| Market Facilitation Index | 0.07 |
Additional Tools for Esperion Stock Analysis
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Holdings Check your current holdings and cash position to determine if your portfolio needs rebalancing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |